Levofloxacina Aurobindo (Levofloxacin)

Levofloxacin blocks bacterial DNA gyrase and topoisomerase IV, enzymes required for DNA replication and transcription. This inhibition prevents the resealing of DNA strands, leading to bacterial cell death and a broad‑spectrum bactericidal effect.

The specific dose and treatment duration of Levofloxacina Aurobindo are determined by the prescribing clinician based on the infection type, severity, patient age, renal function, and other clinical factors. No standard dosing regimen is provided here.

Safety data for levofloxacin in pregnancy and lactation are limited. It is generally avoided unless the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Compared with older fluoroquinolones, levofloxacin offers once‑daily dosing and a broader spectrum against Gram‑negative pathogens. Relative to beta‑lactams, it provides rapid bactericidal activity but carries class‑specific risks such as tendon injury and QT prolongation, which must be weighed against clinical benefits.

Store the product at room temperature below 25 °C in its original packaging. Protect it from moisture, excessive heat, and direct sunlight. Keep the container tightly closed and out of reach of children.

Levofloxacina Aurobindo is administered orally. The tablet should be swallowed whole with a full glass of water. It may be taken with or without food, but antacids containing aluminum, magnesium, or calcium should be spaced at least two hours apart to avoid reduced absorption.

Serious adverse events include tendon rupture (especially in older adults or those on corticosteroids), QT interval prolongation leading to arrhythmias, severe hypersensitivity reactions such as anaphylaxis or Stevens‑Johnson syndrome, and Clostridioides difficile‑associated colitis. Patients should seek immediate medical attention if they experience sudden joint pain, palpitations, or severe skin reactions.

Levofloxacina Aurobindo is contraindicated in individuals with a known hypersensitivity to levofloxacin, other fluoroquinolones, or any component of the formulation. It should also be avoided in patients with a history of tendon disorders related to fluoroquinolone use, those with uncontrolled QT prolongation, and generally in pregnancy or breastfeeding unless no safer alternative exists.